Calcific aortic valve disease (CAVD) is the most frequent form of val-vular pathology [1,2], with high percentages of mortality and morbidityin Western populations, so much to be a very public health problem [2].Diverse millions of subjects are affected by CAVD and the major numberare old individuals (65- older), even if some have a younger age and aregenerally affected by congenital bicuspid aortic valve (BAV) disease[2,3]. CAVD in BAV individuals arises decades earlier respect to subjectswith the physiological tricuspid aortic valve [3]. Furthermore, it can leadto death if untreated with surgical aortic valve replacement or trans-catheter aortic valve implantation, its unique treatments [2]. No phar-macological drugs have been developed for CAVD, because itspathophysiology remains unknown, with mechanisms and pathwaysfully questionable [

Balistreri C.R. (2020). To the research of treatments for the typical calcific disease of old aortic valve in the omics era: Is the miR-195 a therapeutic signature via targetable p38-MAPK/VWF axis in bicuspid aortic valve?. INTERNATIONAL JOURNAL OF CARDIOLOGY, 309, 108-109 [10.1016/j.ijcard.2020.03.023].

To the research of treatments for the typical calcific disease of old aortic valve in the omics era: Is the miR-195 a therapeutic signature via targetable p38-MAPK/VWF axis in bicuspid aortic valve?

Balistreri C. R.
2020

Abstract

Calcific aortic valve disease (CAVD) is the most frequent form of val-vular pathology [1,2], with high percentages of mortality and morbidityin Western populations, so much to be a very public health problem [2].Diverse millions of subjects are affected by CAVD and the major numberare old individuals (65- older), even if some have a younger age and aregenerally affected by congenital bicuspid aortic valve (BAV) disease[2,3]. CAVD in BAV individuals arises decades earlier respect to subjectswith the physiological tricuspid aortic valve [3]. Furthermore, it can leadto death if untreated with surgical aortic valve replacement or trans-catheter aortic valve implantation, its unique treatments [2]. No phar-macological drugs have been developed for CAVD, because itspathophysiology remains unknown, with mechanisms and pathwaysfully questionable [
Balistreri C.R. (2020). To the research of treatments for the typical calcific disease of old aortic valve in the omics era: Is the miR-195 a therapeutic signature via targetable p38-MAPK/VWF axis in bicuspid aortic valve?. INTERNATIONAL JOURNAL OF CARDIOLOGY, 309, 108-109 [10.1016/j.ijcard.2020.03.023].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S016752732030509X-main (1).pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 212.2 kB
Formato Adobe PDF
212.2 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/431318
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact